Provided by Tiger Trade Technology Pte. Ltd.

Mesabi

33.98
-0.0500-0.15%
Post-market: 33.980.00000.00%17:46 EST
Volume:23.01K
Turnover:782.69K
Market Cap:445.82M
PE:25.91
High:34.56
Open:33.53
Low:33.42
Close:34.03
52wk High:42.38
52wk Low:22.55
Shares:13.12M
Float Shares:13.11M
Volume Ratio:0.51
T/O Rate:0.18%
Dividend:1.28
Dividend Rate:3.77%
EPS(TTM):1.31
EPS(LYR):7.11
ROE:29.57%
ROA:17.07%
PB:21.14
PE(LYR):4.78

Loading ...

Mesoblast (ASX:MSB) Is Up 6.7% After Adult Ryoncil Data Readout Validates Earlier Second-Line Use

Simply Wall St.
·
Yesterday

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

GlobeNewswire
·
Feb 12

Mesoblast (ASX:MSB) Is Down 7.4% After Expanding Ryoncil Access And Planning Adult SR-aGvHD Trial – Has The Bull Case Changed?

Simply Wall St.
·
Feb 05

Mesabi Trust Reports $4.9 Million in Quarterly Royalty Payments

Reuters
·
Feb 04

Mesoblast (ASX:MSB) Is Up 8.0% After Ryoncil’s Early Adoption And Adult Expansion Push - Has The Bull Case Changed?

Simply Wall St.
·
Jan 29

Ryoncil® Net Revenues Increase for the Quarter to US$30M

GlobeNewswire
·
Jan 29

Mesoblast (ASX:MSB) Valuation Check As Ryoncil Access And Early Commercial Outcomes Progress

Simply Wall St.
·
Jan 28

Saber Integrates with Circle Payments Network to Strengthen Global Off-Ramp Capabilities

prnewswire
·
Jan 27

Saber Integrates with Circle Payments Network to Strengthen Global Off-Ramp Capabilities

prnewswire
·
Jan 27

Malaysian Stocks Hit Seven-Year High; MSB Global Shares Drop 5%

MT Newswires Live
·
Jan 27

MSB Global Unit, Zhejiang GSP&DC Eye Malaysia's Energy Storage Market; Shares Drop 5%

MT Newswires Live
·
Jan 27

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

GlobeNewswire
·
Jan 27

Mesoblast (ASX:MSB) Is Down 6.4% After Encouraging FDA Feedback On Back Pain Cell Therapy Data – Has The Bull Case Changed?

Simply Wall St.
·
Jan 22

Mesoblast (ASX:MSB) Valuation Check After FDA Backs Rexlemestrocel L’s Pain And Opioid Reduction Data

Simply Wall St.
·
Jan 21

Mesabi Trust Down Over 11%, on Pace for Largest Percent Decrease Since February 2025 -- Data Talk

Dow Jones
·
Jan 21

Press Release: Mesabi Trust Press Release

Dow Jones
·
Jan 17

Does Mesoblast’s New Board Leadership After First FDA Approval Change The Bull Case For ASX:MSB?

Simply Wall St.
·
Jan 15

New Crypto Exchange BitGW Offers Secure and Compliant Trading: Review

utoday
·
Jan 10

Mesoblast (ASX:MSB) Valuation Check As Leadership Changes And Debt Refinancing Reset Expectations

Simply Wall St.
·
Jan 09

Malaysian Shares End in Red Bucking Regional Gains; MSB Global's Shares Rally 18%

MT Newswires Live
·
Jan 06